Following a year-long collaboration, Monsenso signs a three-year + DKK 10 million agreement with a global pharmaceutical company. Monsenso's mobile health solution will be used for real-world data collection across two studies in connection with the launch of a new drug for depression treatment. The studies are expected to start in the first half of 2021 and will run over a three-year period, covering up to 2,250 patients and 120 clinicians across Belgium, the Netherlands, the United Kingdom, Switzerland, Italy, Spain, Denmark, Sweden and France. In connection with the two studies, Monsenso's solution will be used to collect data from patients and their relatives through clinical questionnaires, daily self-assessments and behavioral data from smartphones and wearables. In addition, the patients will be offered in-app study information and can receive reminders about medication and consultations with their clinician. Monsenso's unique mobile health solution will in this way help increase the quality of clinical studies with real-time data collection while also also facilitating better communication between patients, caregivers and clinicians.